Market News & Trends
Processa Successfully Identifies Next-Generation Capecitabine Dosage Regimens for Phase 2B Trial
Processa Pharmaceuticals, Inc. recently announced positive results from its ongoing Next-Generation Capecitabine (NGC) Phase 1B trial. The data collected has allowed Processa to estimate the…
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
Eterna Therapeutics Inc. recently announced it has entered into a sponsored research agreement with Michael Andreeff, MD, PhD, Professor of Leukemia at The University of Texas MD Anderson Cancer Center (MD Anderson)…..
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of a Novel Oral Immune Checkpoint Inhibitor
Teon Therapeutics recently announced the first patient has been treated in its Phase 1/2 clinical trial evaluating the safety and efficacy of TT-816, an oral…
Gilead Sciences is Partnering With the ISPE Foundation to Establish a New Technology Without Borders Initiative
The ISPE Foundation announced Gilead Sciences, Inc. is partnering with the Foundation to establish a new Technology Without Borders initiative. This new program was created to….
Vaccitech Doses First Patients in Phase 2b Clinical Trial of VTP-300 Immunotherapeutic Candidate
Vaccitech plc recently announced the dosing of the first patients in HBV003, a Phase 2b clinical trial designed to further evaluate the safety and efficacy…
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes & Completion of Phase 1 Healthy Volunteer Portion of Phase 1/2 Study
Biomea Fusion, Inc. recently announced the dosing of the first patient with type 2 diabetes in the Phase 2 portion of COVALENT-111, a Phase 1/2…
Gerresheimer & Merck KGaA Transform Primary Packaging Into Digital Twins
Gerresheimer AG and Merck KGaA, Darmstadt, Germany, jointly developed a digital twin solution to further ensure traceability and trust in crucial steps along the pharmaceutical…
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership With Emergent BioSolutions
SAB Biotherapeutics recently announced the company has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc. Emergent will provide….
Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned subsidiary of SWK Holdings Corporation…
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells & Hair Follicles
Aileron Therapeutics recently presented detailed results from its completed Phase 1 study of ALRN-6924 in healthy volunteers at the EORTC-NCI-AACR International Conference on Molecular Targets…
VacV Biotherapeutics Emerges From Stealth Mode to Bring Ground-Breaking Cancer Immunotherapies to the Clinic
VacV Biotherapeutics recently emerged from stealth mode to advance its promising pipeline of preclinical assets with best-in-class potential, toward the clinic…..
Panoramic Health Launches Clinical Research Division to Drive Discovery of Novel Kidney Disease Therapies
Panoramic Health recently announced the launch of its clinical research division dedicated to advancing kidney care innovation and improving patient outcomes….
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
eFFECTOR Therapeutics, Inc. recently announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical trial of zotatifin in non-hospitalized…
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 & BDTX-4933
Black Diamond Therapeutics, Inc. recently announced the presentation of three posters reporting new preclinical data on BDTX-1535 and BDTX-4933 at the 34th European Organisation for…
Symeres Acquires Exemplify BioPharma, Further Strengthening its Strategic Foothold in the US
Symeres recently announced the acquisition of Exemplify BioPharma, a US based CRO that provides integrated drug development services in Process & Analytical Chemistry and….
Lonza joins GENEGUT Project to Develop a Capsule Delivery Solution for an Innovative Crohn's Disease Treatment
Lonza recently announced its participation in the GENEGUT project to develop an innovative functional capsule-based delivery solution for therapies targeting….
George Clinical Recruits More than 5,000 Patients in the Global Kidney Patient Trials Network
George Clinical, in close collaboration with The George Institute for Global Health, recently announced the recruitment of more than 5,000 patients in its ground-breaking, first…
Lonza Expands Global Process Development Team & Laboratory Spaces for Cell & Gene Development
Lonza recently announced it is expanding its cell and gene therapies (CGT) process and analytical development laboratories at its locations in Houston, TX, and Geleen…
Acumen’s Anti-Amyloid Beta Oligomer Antibody Granted FDA Fast Track Designation for Alzheimer's Disease
Acumen Pharmaceuticals, Inc. recently announced ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs), has been granted Fast Track designation for the treatment of early Alzheimer’s disease by….
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease
Phathom Pharmaceuticals, Inc. recently announced it has completed enrollment in its PHALCON-NERD Daily Dosing Phase 3 trial of vonoprazan in non-erosive gastroesophageal reflux disease (NERD).…
